Kathleen Mullane to Adult
This is a "connection" page, showing publications Kathleen Mullane has written about Adult.
Connection Strength
0.538
-
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2019 01 07; 68(2):196-203.
Score: 0.041
-
Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 2018 Aug; 61(8):518-533.
Score: 0.040
-
Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host. Transpl Infect Dis. 2016 Oct; 18(5):785-790.
Score: 0.035
-
Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial. J Antimicrob Chemother. 2016 10; 71(10):2964-71.
Score: 0.035
-
Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother. 2015 Mar; 59(3):1435-40.
Score: 0.031
-
Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013 Nov 01; 208(9):1375-85.
Score: 0.028
-
Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol. 2013; 38(1):1-11.
Score: 0.028
-
Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011 Sep; 53(5):440-7.
Score: 0.025
-
Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis. 2007 Jun; 9(2):89-96.
Score: 0.019
-
Pseudo-SARS. N Engl J Med. 2003 Aug 14; 349(7):709-11; author reply 709-11.
Score: 0.014
-
American Society for Transplantation and Cellular Therapy Series: #5-Management of Clostridioides difficile Infection in Hematopoietic Cell Transplant Recipients. Transplant Cell Ther. 2022 05; 28(5):225-232.
Score: 0.013
-
Cording in Disseminated Mycobacterium chelonae Infection in an Immunocompromised Patient. Lab Med. 2021 May 04; 52(3):e50-e52.
Score: 0.012
-
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. Clin Infect Dis. 2020 12 31; 71(11):2777-2786.
Score: 0.012
-
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 11 05; 383(19):1827-1837.
Score: 0.011
-
Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: A preliminary report. J Clin Exp Neuropsychol. 1999 Oct; 21(5):730-5.
Score: 0.011
-
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):369-381.
Score: 0.010
-
Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018 05 26; 391(10135):2116-2127.
Score: 0.010
-
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses. 2018 Jul; 61(7):485-497.
Score: 0.010
-
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. Mycoses. 2018 Jul; 61(7):420-429.
Score: 0.010
-
Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. J Antimicrob Chemother. 2018 03 01; 73(3):757-763.
Score: 0.010
-
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017 12 21; 377(25):2433-2444.
Score: 0.010
-
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017 Dec 01; 72(12):3406-3413.
Score: 0.010
-
The Impact of Recurrent Clostridium difficile Infection on Patients' Prevention Behaviors. Infect Control Hosp Epidemiol. 2017 11; 38(11):1351-1357.
Score: 0.009
-
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016 Jul; 16(7):828-837.
Score: 0.009
-
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. Clin Infect Dis. 2016 Mar 01; 62(5):596-602.
Score: 0.008
-
Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis. PLoS One. 2015; 10(6):e0129022.
Score: 0.008
-
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014 May 08; 370(19):1781-9.
Score: 0.007
-
CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013 Sep 26; 369(13):1227-36.
Score: 0.007
-
Histoplasmosis after solid organ transplant. Clin Infect Dis. 2013 Dec; 57(11):1542-9.
Score: 0.007
-
Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013 Jul 01; 31(19):2493-9.
Score: 0.007
-
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012 Aug; 55 Suppl 2:S121-6.
Score: 0.007
-
Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 03; 364(5):422-31.
Score: 0.006
-
Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2009 Jan; 53(1):223-8.
Score: 0.005
-
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007 Apr; 39(7):425-9.
Score: 0.005
-
Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006 Jan; 50(1):126-33.
Score: 0.004
-
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005 Oct; 24(10):654-61.
Score: 0.004
-
Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial. Thromb Haemost. 2004 Sep; 92(3):575-82.
Score: 0.004
-
Clinical and magnetic resonance imaging regression of progressive multifocal leukoencephalopathy in an AIDS patient after intensive antiretroviral therapy. J Neuroimaging. 2001 Jul; 11(3):336-9.
Score: 0.003
-
Verbal working memory in HIV-seropositive drug users. J Int Neuropsychol Soc. 2000 Jul; 6(5):548-55.
Score: 0.003
-
Impaired phagocyte oxidative capacity in patients with human immunodeficiency virus infection. J Lab Clin Med. 1998 Oct; 132(4):284-93.
Score: 0.003
-
Information processing and antiretroviral therapy in HIV-1 infection. J Int Neuropsychol Soc. 1998 Jul; 4(4):329-35.
Score: 0.002
-
Working memory deficits in HIV-seropositive drug users. J Int Neuropsychol Soc. 1997 Sep; 3(5):451-6.
Score: 0.002
-
Delayed recognition memory span in HIV-1 infection. J Int Neuropsychol Soc. 1995 Nov; 1(6):575-80.
Score: 0.002